ScholarWorks@Hanyang University

Browsing by Miyasaka, NobuyukiAuthor

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
전체 가 나 다 라 마 바 사 아 자 차 카 타 파 하

Showing results 1 to 3 of 3

SCIESCOPUS
A comparison of incidence and risk factors for serious adverse events in rheumatoid arthritis patients with etanercept or adalimumab in Korea and JapanGo to Link

Cho, Soo-Kyung; Sakai, Ryoko; Nanki, Toshihiro; Koike, Ryuji; Watanabe, Kaori; Yamazaki, Hayato; Nagasawa, Hayato; Tanaka, Yoshiya; Nakajima, Atsuo; Yasuda, Shinsuke, et al.

ArticleIssue Date2014CitationModern Rheumatology, v.24, no.4, pp 572 - 579PublisherSpringer Verlag
SCISCIESCOPUS
Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registryGo to Link

Sakai, Ryoko; Cho, Soo-Kyung; Nanki, Toshihiro; Watanabe, Kaori; Yamazaki, Hayato; Tanaka, Michi; Koike, Ryuji; Tanaka, Yoshiya; Saito, Kazuyoshi; Hirata, Shintaro, et al.

ArticleIssue Date2015CitationArthritis Research & Therapy, v.17, pp 1 - 10PublisherBioMed Central
SCISCIESCOPUS
The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) databaseGo to Link

Sakai, Ryoko; Cho, Soo-Kyung; Nanki, Toshihiro; Koike, Ryuji; Watanabe, Kaori; Yamazaki, Hayato; Nagasawa, Hayato; Amano, Koichi; Tanaka, Yoshiya; Sumida, Takayuki, et al.

ArticleIssue Date2014CitationRheumatology International, v.34, no.12, pp 1729 - 1736PublisherSpringer Verlag
1
CONTACT US

RSS_1.0 RSS_2.0 ATOM_1.0

222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366

COPYRIGHT © 2024 HANYANG UNIVERSITY.

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

BROWSE

한국어